Today on Health in 2 Point 00, we’re wishing Jess a happy belated birthday! On Episode 189, Jess asks me about DispatchHealth raising a massive $200 million Series D, bringing their total up to $403 million, providing in-home urgent care. TytoCare raises another $50 million… Read More »#Healthin2Point00, Episode 189 | DispatchHealth, TytoCare and Highmark Health
Verily become part of a six-year collaboration between Google Cloud and Highmark Health. A big part of the partnership will be Verily’s platform for managing chronic conditions, Onduo.
What You Should Know: – Highmark Health has engaged Verily to build out digital health tools for patients and analytics solutions for Highmark’s clinicians as part of its Living Health model. This marks the first collaboration of its kind for Verily, Google Cloud and a partner. – Highmark Health… Read More »Highmark Health Taps Verily to Build Digital Health Tools for Living Health Model
What You Should Know: – Verily’s Onduo, known for its tech-based solution for virtual diabetes management, is launching a new multi-condition platform that matches the right care to the right consumer at the right time. The expanded virtual care platform is designed to support patients managing type 2… Read More »Verily’s Onduo Virtual Care Solution Expands to Multi-Condition Platform
Verily’s virtual diabetes platform, Onduo, is expanding to support additional conditions and languages, Onduo’s CEO Vindell Washington shared. How will the company differentiate itself among a growing number of multi-condition platforms, such as Livongo and Omada?
Verily is planning “significant and focused growth” in 2021 after closing a $700 million funding round from investors including its parent company, and Google holding firm, Alphabet. The capital injection will support wide-ranging plans for the new year that include several life sciences programmes in… Read More »Google’s Verily eyes 2021 growth after £700m funding round
Alphabet and other investors poured $700 million in funding into Verily last week. The company, which is Alphabet’s life sciences subsidiary, plans to pour some of the funds into supporting Covid-19 vaccine studies and programs for businesses.